Patents by Inventor Robert Schmouder

Robert Schmouder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage regimen of an S1P receptor modulator
    Patent number: 11759436
    Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection caused by varicella zoster virus and vaccinating the patient prior to administration of an S1P receptor modulator or agonist.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 19, 2023
    Assignee: Novartis AG
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder, William C. Collins
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20230086687
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 23, 2023
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20220142949
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: September 20, 2021
    Publication date: May 12, 2022
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20210023027
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutical/acceptable salt thereof, and to the use thereof far treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: October 7, 2020
    Publication date: January 28, 2021
    Inventors: John M. Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20200330407
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20200222338
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER, William C. COLLINS
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20200197334
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Inventors: John M. Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • Dosage regimen of an S1P receptor modulator
    Patent number: 10543179
    Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: January 28, 2020
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder, William C. Collins
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20190358178
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Inventors: John M. Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • Paediatric Compositions for Treating Multiple Sclerosis
    Publication number: 20190117593
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a pediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 25, 2019
    Inventors: John Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20190091180
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20180289638
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20180263930
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20180263929
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20180177747
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20- alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Inventors: John M. Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20170333368
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-C20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: August 8, 2017
    Publication date: November 23, 2017
    Inventors: Marie-Claude Bastien, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20170304226
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20170189353
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • Paediatric Compositions For Treating Multiple Sclerosis
    Publication number: 20170128389
    Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 11, 2017
    Inventors: John M. Kovarik, Robert Schmouder, Marie-Claude Bastien, Olivier David, Goeril Karlsson
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20160263061
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Applicant: Novartis AG
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY